25 completed, 12 recruiting, 7 active not recruiting, 4 terminated. 26 Phase 2, 17 Phase 3, 9 Phase 1, 1 Not applicable.
Follow Autologous Stem Cell Transplant: new trials by email Literature Review of Autologous Stem Cell Transplant trials Research Report on Autologous Stem Cell Transplant
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Testing an Experimental Approach to Treat Patients With Plasma Cell Leukemia, The QUANTUM Trial Autologous Hematopoietic Stem Cell Transplantation, Biospecimen Collection, Bone Marrow Aspiration - Plasma Cell Leukemia | Phase 2 | Recruiting | National Cancer Institute (NCI) | 74 | 2027-04-20 | 2026-10-07 |
| Evaluating the Addition of Maintenance Immunotherapy Compared to the Usual Treatment of Chemotherapy and Autologous Stem Cell Transplant Alone for High-risk Patients With Relapsed or Refractory Hodgkin Lymphoma 3-Dimensional Conformal Radiation Therapy, Autologous Hematopoietic Stem Cell Transplantation, Biospecimen Collection - Recurrent Classic Hodgkin Lymphoma, Refractory Classic Hodgkin Lymphoma | Phase 2 / Phase 3 | Not yet recruiting | National Cancer Institute (NCI) | 374 | 2026-12-04 | 2026-07-08 |
| Epcoritamab, Rituximab, Gemcitabine and Oxaliplatin (R-GemOx) as Salvage Therapy Before Autologous Stem Cell Transplant for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma Autologous Hematopoietic Stem Cell Transplantation, Biopsy Procedure, Biospecimen Collection - Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Recurrent High Grade B-Cell Lymphoma, Not Otherwise Specified | Phase 2 | Recruiting | City of Hope Medical Center | 43 | 2026-07-27 | 2026-08-28 |
| Epcoritamab Plus Standard of Care Platinum-Based Chemotherapy and Autologous Hematopoietic Cell Transplant for the Treatment of Relapsed or Refractory Large B-cell Lymphoma Autologous Hematopoietic Stem Cell Transplantation, Carboplatin, Cytarabine - Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified | Phase 2 | Recruiting | University of California, Davis | 25 | 2025-07-31 | 2026-06-30 |
| Testing Whether High Dose Chemotherapy and Infusion of the Patients' Own Stem Cells Improves Survival in Patients With Peripheral T-cell Lymphoma Who Achieved a Complete Response at the End of the Initial Chemotherapy Autologous Hematopoietic Stem Cell Transplantation, Best Practice, Biospecimen Collection - Anaplastic Large Cell Lymphoma, ALK-Negative, Follicular Helper T-Cell Lymphoma | Phase 3 | Recruiting | Eastern Cooperative Oncology Group | 294 | 2025-06-18 | 2026-09-14 |
| CNS-Relapse Prevention in High-Risk Diffuse Large B-cell Lymphoma With Thiotepa-based Autologous Stem Cell Transplant Thiotepa, Carmustine, Autologous Stem Cell Transplant - Diffuse Large B Cell Lymphoma | Phase 2 | Recruiting | Washington University School of Medicine | 36 | 2025-01-16 | 2026-08-28 |
| MT2022-60: Ph 2 Study of Pembro+ BEAM With ASCT for Relapsed Hodgkin Lymphoma Pembrolizumab, Autologous stem cell transplant, Carmustine - Autologous Stem Cell Transplant, Classic Hodgkin Lymphoma | Phase 2 | Recruiting | Masonic Cancer Center, University of Minnesota | 28 | 2024-12-04 | 2026-09-29 |
| High Dose Ruxolitinib and Allogeneic Stem Cell Transplantation in Myelofibrosis Patients With Splenomegaly Ruxolitinib, Allogeneic Stem Cell Transplantation, Levetiracetam - Splenomegaly, Myelofibrosis | Phase 2 | Recruiting | M.D. Anderson Cancer Center | 30 | 2024-10-01 | 2026-09-16 |
| Pre-transplant Purging and Post-transplant MRD-guided Maintenance Therapy With Elranatamab in Patients With High-risk Multiple Myeloma Elranatamab, Lenalidomide, Plerixafor - Multiple Myeloma, Post-transplant MRD-guided Maintenance Therapy | Phase 2 | Recruiting | M.D. Anderson Cancer Center | 40 | 2024-07-17 | 2026-08-10 |
| Comparing Dara-VCD Chemotherapy Plus Stem Cell Transplant to Dara-VCD Chemotherapy Alone for People Who Have Newly Diagnosed AL Amyloidosis Autologous Hematopoietic Stem Cell Transplantation, Biopsy, Biospecimen Collection - AL Amyloidosis | Phase 3 | Recruiting | SWOG Cancer Research Network | 338 | 2024-07-01 | 2026-05-06 |
| A Trial Comparing Chemotherapy Versus Novel Immune Checkpoint Inhibitor (Pembrolizumab) Plus Chemotherapy in Treating Relapsed/Refractory Classical Hodgkin Lymphoma Autologous Hematopoietic Stem Cell Transplantation, Bendamustine, Brentuximab Vedotin - Recurrent Classic Hodgkin Lymphoma, Refractory Classic Hodgkin Lymphoma | Phase 3 | Withdrawn | National Cancer Institute (NCI) | 2023-08-10 | 2024-03-20 | |
| Loncastuximab Tesirine in Combination With Chemotherapy Prior to Stem Cell Transplant for the Treatment of Recurrent or Refractory Diffuse Large B-Cell Lymphoma Autologous Hematopoietic Stem Cell Transplantation, Carmustine, Cytarabine - Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified | Phase 1 | Withdrawn | Fred Hutchinson Cancer Center | 2023-04-01 | 2023-01-13 | |
| Expression-linked and R-ISS-adapted Stratification for First Line Therapy in Multiple Myeloma Patients Isatuximab, Lenalidomide, Bortezomib - Newly Diagnosed Multiple Myeloma | Phase 2 / Phase 3 | Recruiting | University Hopsital Schleswig Holstein Campus Lübeck | 100 | 2023-02-03 | 2024-12-11 |
| Multiple Myeloma Outcomes Based on Maintenance Therapy Post Autologous Stem Cell Transplant Autologous Stem Cell Transplant, Immunomodulatory Agent, Proteasome Inhibitor - Multiple Myeloma | Active not recruiting | H. Lee Moffitt Cancer Center and Research Institute | 69 | 2022-04-20 | 2026-03-02 | |
| Dinutuximab, Sargramostim, and Combination Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma Autologous Hematopoietic Stem Cell Transplantation, Carboplatin, Cisplatin - Ganglioneuroblastoma, High Risk Neuroblastoma | Phase 2 | Completed | National Cancer Institute (NCI) | 42 | 2019-03-04 | 2026-06-02 |
| Evaluation of 2 Intensification Treatment Strategies for Neuroblastoma Patients With a Poor Response to Induction mIBG, Topotecan, Thiotepa - Very High Risk Neuroblastoma | Phase 2 | Terminated | Gustave Roussy, Cancer Campus, Grand Paris | 34 | 2018-10-01 | 2025-09-02 |
| Elotuzumab in Combination With Carfilzomib, Lenalidomide and Dexamethasone (E-KRd) Versus KRd in MM Elotuzumab, Carfilzomib, Lenalidomide - Newly Diagnosed Multiple Myeloma | Phase 3 | Active not recruiting | Wuerzburg University Hospital | 576 | 2018-08-28 | 2023-05-06 |
| Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL) Autologous Hematopoietic Stem Cell Transplantation, Biospecimen Collection, Bone Marrow Aspiration and Biopsy - Ganglioneuroblastoma, Ganglioneuroblastoma, Nodular | Phase 3 | Recruiting | Children's Oncology Group | 750 | 2018-05-14 | 2026-08-25 |
| Daratumumab in Treating Transplant-Eligible Patients With Multiple Myeloma Autologous Hematopoietic Stem Cell Transplantation, Daratumumab, Lenalidomide - Plasma Cell Myeloma | Phase 2 | Completed | Mayo Clinic | 49 | 2018-04-09 | 2026-05-05 |
| Autologous Stem Cell Transplant for Crohn's Disease Autologous stem cell transplant, Cyclophosphamide, Thymoglobulin - Crohn Disease | Phase 2 | Recruiting | Aaron Etra | 50 | 2018-02-22 | 2026-07-24 |
Showing 20 of 52. Sign in to see all of them.
Multiple Myeloma (15) · Lymphoma, Large B-Cell, Diffuse (8) · Ganglioneuroblastoma (4) · Lymphoma (4) · Lymphoma, Non-Hodgkin (4) · Neuroblastoma (4) · Immunoglobulin Light-chain Amyloidosis (3) · Lymphoma, Mantle-Cell (3) · Neoplasms, Plasma Cell (3) · Hodgkin Disease (2) · Central Nervous System Neoplasms (1) · Colitis (1) · Crohn Disease (1) · Gastroenteritis (1) · Hematologic Diseases (1)
National Cancer Institute (NCI) (7) · Children's Oncology Group (6) · City of Hope Medical Center (3) · H. Lee Moffitt Cancer Center and Research Institute (3) · M.D. Anderson Cancer Center (3) · Washington University School of Medicine (3) · Lymphoma Study Association (2) · Royal Marsden NHS Foundation Trust (2) · Wuerzburg University Hospital (2) · Aaron Etra (1) · Dana-Farber Cancer Institute (1) · ECOG-ACRIN Cancer Research Group (1) · Eastern Cooperative Oncology Group (1) · Fred Hutchinson Cancer Center (1) · Gustave Roussy, Cancer Campus, Grand Paris (1)
United States (41) · Australia (5) · Canada (5) · France (3) · Germany (3) · Austria (2) · New Zealand (2) · Puerto Rico (2) · Saudi Arabia (2) · United Kingdom (2) · Argentina (1) · Brazil (1) · Egypt (1) · Italy (1) · Mexico (1)
David Cunningham, FRCP (2) · Hermann Einsele, MD (2) · Vaishalee P Kenkre (2) · Aaron Etra, MD (1) · Alyssa T Reddy (1) · Amanda F Cashen, M.D. (1) · Amrita Y. Krishnan MD, MD (1) · Armin Ghobadi, M.D. (1) · Attaphol Pawarode, M.D. (1) · Brad S Kahl, M.D. (1) · Brian D Weiss (1) · Charalambos B Andreadis (1) · Claire M Mazewski (1) · Corinne Haioun (1) · Corinne Haioun, MD (1)
PMID 34028986, PMID 22571201, PMID 25204639, PMID 26373676, PMID 27118452, PMID 28826616, PMID 30959163, PMID 32126141, PMID 32730180, PMID 33288485, PMID 33461512, PMID 34492682, PMID 34515338, PMID 34549906, PMID 35132679, PMID 35660812, PMID 35820112, PMID 36485104, PMID 37871306, PMID 39515374
U10CA180886 (7), U10CA098543 (5), U10CA180820 (4), U10CA180821 (4), P30CA033572 (2), U10CA031946 (2), 2009 (1), 2015 (1), 2017 (1), P30CA086862 (1), P30CA093373 (1), P50CA107399 (1), U01HL069294 (1), U10CA180888 (1)